FDA Calls for Withdrawal of Multiple Myeloma Drug Pepaxto

The drug was granted an accelerated approval, but a confirmatory phase 3 trial raised concerns about safety after showing higher mortality than in the comparator arm.

Related Keywords

United States ,Jakob Lindberg ,Oncologic Drugs Advisory Committee ,European Medicines Agency ,Drug Administration ,Healthcare Products Regulatory Agency ,Drugs Advisory Committee ,Medscape Medical News ,United Kingdom ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,United Kingdom Site Content ,